These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

786 related articles for article (PubMed ID: 25884642)

  • 1. Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model.
    Brandes F; Schmidt K; Wagner C; Redekopf J; Schlitt HJ; Geissler EK; Lang SA
    BMC Cancer; 2015 Feb; 15():71. PubMed ID: 25884642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer.
    Taeger J; Moser C; Hellerbrand C; Mycielska ME; Glockzin G; Schlitt HJ; Geissler EK; Stoeltzing O; Lang SA
    Mol Cancer Ther; 2011 Nov; 10(11):2157-67. PubMed ID: 21885862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual Inhibition of Hedgehog and c-Met Pathways for Pancreatic Cancer Treatment.
    Rucki AA; Xiao Q; Muth S; Chen J; Che X; Kleponis J; Sharma R; Anders RA; Jaffee EM; Zheng L
    Mol Cancer Ther; 2017 Nov; 16(11):2399-2409. PubMed ID: 28864680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis.
    Xu Z; Pang TCY; Liu AC; Pothula SP; Mekapogu AR; Perera CJ; Murakami T; Goldstein D; Pirola RC; Wilson JS; Apte MV
    Br J Cancer; 2020 May; 122(10):1486-1495. PubMed ID: 32203220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer.
    Pothula SP; Xu Z; Goldstein D; Biankin AV; Pirola RC; Wilson JS; Apte MV
    Br J Cancer; 2016 Feb; 114(3):269-80. PubMed ID: 26766740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nicotine Reduces Survival via Augmentation of Paracrine HGF-MET Signaling in the Pancreatic Cancer Microenvironment.
    Delitto D; Zhang D; Han S; Black BS; Knowlton AE; Vlada AC; Sarosi GA; Behrns KE; Thomas RM; Lu X; Liu C; George TJ; Hughes SJ; Wallet SM; Trevino JG
    Clin Cancer Res; 2016 Apr; 22(7):1787-99. PubMed ID: 26667487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model.
    Yokoi K; Sasaki T; Bucana CD; Fan D; Baker CH; Kitadai Y; Kuwai T; Abbruzzese JL; Fidler IJ
    Cancer Res; 2005 Nov; 65(22):10371-80. PubMed ID: 16288027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models.
    Feldmann G; Mishra A; Bisht S; Karikari C; Garrido-Laguna I; Rasheed Z; Ottenhof NA; Dadon T; Alvarez H; Fendrich V; Rajeshkumar NV; Matsui W; Brossart P; Hidalgo M; Bannerji R; Maitra A; Nelkin BD
    Cancer Biol Ther; 2011 Oct; 12(7):598-609. PubMed ID: 21768779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
    Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
    Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of AKT2 enhances sensitivity to gemcitabine via regulating PUMA and NF-κB signaling pathway in human pancreatic ductal adenocarcinoma.
    Chen D; Niu M; Jiao X; Zhang K; Liang J; Zhang D
    Int J Mol Sci; 2012; 13(1):1186-1208. PubMed ID: 22312312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. INC280, an orally available small molecule inhibitor of c-MET, reduces migration and adhesion in ovarian cancer cell models.
    Moran-Jones K; Brown LM; Samimi G
    Sci Rep; 2015 Jul; 5():11749. PubMed ID: 26138303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancer.
    Hashim YM; Vangveravong S; Sankpal NV; Binder PS; Liu J; Goedegebuure SP; Mach RH; Spitzer D; Hawkins WG
    J Exp Clin Cancer Res; 2017 Jan; 36(1):14. PubMed ID: 28095907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing endosomal escape.
    Lee JE; Kang YW; Jung KH; Son MK; Shin SM; Kim JS; Kim SJ; Fang Z; Yan HH; Park JH; Yoon YC; Han B; Cheon MJ; Woo MG; Seo MS; Lim JH; Kim YS; Hong SS
    Cancer Lett; 2021 Jun; 507():97-111. PubMed ID: 33744388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-targeting of CXCR4 and hedgehog pathways disrupts tumor-stromal crosstalk and improves chemotherapeutic efficacy in pancreatic cancer.
    Khan MA; Srivastava SK; Zubair H; Patel GK; Arora S; Khushman M; Carter JE; Gorman GS; Singh S; Singh AP
    J Biol Chem; 2020 Jun; 295(25):8413-8424. PubMed ID: 32358063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
    Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
    Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
    Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
    Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer.
    Banerjee S; Zhang Y; Ali S; Bhuiyan M; Wang Z; Chiao PJ; Philip PA; Abbruzzese J; Sarkar FH
    Cancer Res; 2005 Oct; 65(19):9064-72. PubMed ID: 16204081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Piperlongumine Suppresses Growth and Sensitizes Pancreatic Tumors to Gemcitabine in a Xenograft Mouse Model by Modulating the NF-kappa B Pathway.
    Wang Y; Wu X; Zhou Y; Jiang H; Pan S; Sun B
    Cancer Prev Res (Phila); 2016 Mar; 9(3):234-44. PubMed ID: 26667450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Side population cells of pancreatic cancer show characteristics of cancer stem cells responsible for resistance and metastasis.
    Niess H; Camaj P; Renner A; Ischenko I; Zhao Y; Krebs S; Mysliwietz J; Jäckel C; Nelson PJ; Blum H; Jauch KW; Ellwart JW; Bruns CJ
    Target Oncol; 2015 Jun; 10(2):215-27. PubMed ID: 24950733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Norleual, a hepatocyte growth factor and macrophage stimulating protein dual antagonist, increases pancreatic cancer sensitivity to gemcitabine.
    Church KJ; Vanderwerff BR; Riggers RR; Mateo-Victoriano B; Fagnan M; Harris PH; LeValley JC; Harding JW
    Anticancer Drugs; 2018 Apr; 29(4):295-306. PubMed ID: 29389804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.